These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36091008)

  • 1. Serum peptidome profiles immune response of COVID-19 Vaccine administration.
    Zhang W; Li D; Xu B; Xu L; Lyu Q; Liu X; Li Z; Zhang J; Sun W; Ma Q; Qiao L; Liao P
    Front Immunol; 2022; 13():956369. PubMed ID: 36091008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Detection of COVID-19 Using MALDI-TOF-Based Serum Peptidome Profiling.
    Yan L; Yi J; Huang C; Zhang J; Fu S; Li Z; Lyu Q; Xu Y; Wang K; Yang H; Ma Q; Cui X; Qiao L; Sun W; Liao P
    Anal Chem; 2021 Mar; 93(11):4782-4787. PubMed ID: 33656857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of MALDI-TOF MS and machine learning for the detection of SARS-CoV-2 and non-SARS-CoV-2 respiratory infections.
    Yegorov S; Kadyrova I; Korshukov I; Sultanbekova A; Kolesnikova Y; Barkhanskaya V; Bashirova T; Zhunusov Y; Li Y; Parakhina V; Kolesnichenko S; Baiken Y; Matkarimov B; Vazenmiller D; Miller MS; Hortelano GH; Turmukhambetova A; Chesca AE; Babenko D
    Microbiol Spectr; 2024 May; 12(5):e0406823. PubMed ID: 38497716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
    Zhang Y; Yang Y; Qiao N; Wang X; Ding L; Zhu X; Liang Y; Han Z; Liu F; Zhang X; Yang X
    Front Med; 2022 Feb; 16(1):93-101. PubMed ID: 35122211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
    Zhao W; Chen W; Li J; Chen M; Li Q; Lv M; Zhou S; Bai S; Wang Y; Zhang L; Zhang P; Wang J; Zheng Q; Wu J
    mBio; 2022 Jun; 13(3):e0018122. PubMed ID: 35475648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
    Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
    Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
    Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
    Front Immunol; 2022; 13():939311. PubMed ID: 36032136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.
    Wang Z; Zhao Z; Cui T; Huang M; Liu S; Su X; Li G; Song T; Li W; Zhong N; Xu M; Yang X; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):829-840. PubMed ID: 35230230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry of the Effects of Preanalytical Variables on Serum Peptidome Profiles Following Long-Term Sample Storage.
    Tsuchida S; Satoh M; Umemura H; Sogawa K; Takiwaki M; Ishige T; Miyabayashi Y; Iwasawa Y; Kobayashi S; Beppu M; Nishimura M; Kodera Y; Matsushita K; Nomura F
    Proteomics Clin Appl; 2018 May; 12(3):e1700047. PubMed ID: 29349874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group.
    Escobar A; Reyes-López FE; Acevedo ML; Alonso-Palomares L; Valiente-Echeverría F; Soto-Rifo R; Portillo H; Gatica J; Flores I; Nova-Lamperti E; Barrera-Avalos C; Bono MR; Vargas L; Simon V; Leiva-Salcedo E; Vial C; Hormazabal J; Cortes LJ; Valdés D; Sandino AM; Imarai M; Acuña-Castillo C
    Front Immunol; 2021; 12():766278. PubMed ID: 35173705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.